TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36746174
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (10 mg/kg per day for 3 days)
Study: 36746174
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (2 g/kg as a single dose)
Study: 36746334
Drug: 7-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7-day regimen of intravenous cefazolin (1 g every 12 hours) and oral clarithromycin (500 mg every 12 hours)
Study: 36746334
Drug: Until-delivery regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Until-delivery regimen of intravenous cefazolin (1 g every 12 hours) and oral clarithromycin (500 mg every 12 hours)
Study: 36746334
Drug: Until-delivery regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Until-delivery regimen of intravenous cefazolin and clarithromycin
Study: 36746334
Drug: 7-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7-day regimen of intravenous cefazolin and clarithromycin
Study: 36746385
Drug: Nelonemdaz (5,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelonemdaz (5,250 mg divided by 10 times for 5 days)
Study: 36746510
Drug: dalutrafusp alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dalutrafusp alfa (0.3, 1, 3, 10, 20, 30, or 45 mg/kg) intravenously every 2 weeks (Q2W) up to 1 year or until progressive disease (PD) or unacceptable toxicity
Study: 36746510
Drug: dalutrafusp alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dalutrafusp alfa (20 mg/kg and higher)
Study: 36746510
Drug: dalutrafusp alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dalutrafusp alfa treatment
Study: 36746739
Drug: Inactivated poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliovirus vaccine (IPV) + double mutant Labile Toxin (dmLT)
Study: 36746739
Drug: Bivalent live
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent live oral polio vaccine (bOPV)
Study: 36746805
Drug: CRAFT (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRAFT (Cognitive Retraining and Functional Treatment)
Study: 36746812
Drug: Intravenous antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotic treatment (Meropenem) for bronchiectasis exacerbations
Study: 36746819
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml of 4% articaine with 1:100,000 epinephrine (4%Ar + Ep)
Study: 36746819
Drug: 0.2 ml
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml of 4% articaine with 1:100,000 epinephrine (4%Ar + Ep)
Study: 36746819
Drug: 0.3 ml
Normalized name: ethanol 0.3 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 ml of 4% articaine with 1:100,000 epinephrine (4%Ar + Ep)
Study: 36746851
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of perampanel 2, 4, or 8 mg
Study: 36746851
Drug: Once-daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral perampanel 2 mg on Days 1-7 and 4 mg on Days 8-21
Study: 36746922
Drug: Supplement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement of PE in statin or fibrate therapy
Study: 36746967
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg orally daily
Study: 36747095
Drug: jRSAID with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: jRSAID with age at onset (AO) < 130 months and disease-modifying therapy (DMT) < 2 months
Study: 36747095
Drug: jRSAID with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: jRSAID with age at onset (AO) < 130 months and disease-modifying therapy (DMT) > 2 months
Study: 36747118
Drug: Pucotenlimab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pucotenlimab (3 mg/kg every 3 weeks until disease progression, intolerable toxicity, or treatment discontinuation)
Study: 36747119
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of bupivacaine for ESPB
Study: 36747119
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of bupivacaine for ESPB
Study: 36747142
Drug: Psychomotor treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychomotor treatment
Study: 36747194
Drug: Enhanced MDA
Normalized name: BK-MDA
DrugBank: BK-MDA (DB12809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced MDA with community-wide treatment followed by 2 rounds of targeted treatment to children (ages 6 months to 9 years) at 2 weeks and 4 weeks after community MDA.
Study: 36747244
Drug: Metformin continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin continuation during coronary angiography
Study: 36747246
Drug: Group-based, online,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based, online, compassion-focussed therapy and breathing pattern retraining intervention for 6 weeks
Study: 36747246
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (treatment as usual)
Study: 36747276
Drug: Intervention (individualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (individualized nutritional therapy + standard of care)
Study: 36748398
Drug: Cytosine methylation
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytosine methylation of the 1F promoter of the glucocorticoid receptor
Study: 36748723
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg) every 3 weeks for up to 35 cycles
Study: 36749104
Drug: Ophthalmic 5%
Normalized name: natamycin ophthalmic 5% ophthalmic suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic 5% povidone-iodine
Study: 36749131
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (oral magnesium hydroxide 15 mmol twice daily for 12 months)
Study: 36749209
Drug: Xenon 129
Normalized name: xenon-129
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xenon 129 treatment, details on dosage and duration not available
Study: 36749255
Drug: PBM application
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBM application twice a week for 4 weeks
Study: 36749255
Drug: Simulated PBM
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated PBM applied twice a week for 4 weeks (Control)
Study: 38289999
Drug: Mineralocorticoid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralocorticoid receptor antagonist
Study: 36750134
Drug: THC (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (8 mg THC for 75 kg person)
Study: 36750134
Drug: THC +
Normalized name: Tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC + CBD (8 mg THC and 24 mg CBD for 75 kg person)
Study: 36750768
Drug: Satisfaction with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satisfaction with treatment results measured by CQLS
Study: 36750858
Drug: Postoperative extensive
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative extensive target volume irradiation with elevated radiation dose and concurrent chemotherapy (5 cycles of weekly TC: paclitaxel 50 mg/m2)
Study: 36750858
Drug: Postoperative extensive
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative extensive target volume irradiation with elevated radiation dose and concurrent chemotherapy
Study: 36750902
Drug: Inactivated COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated COVID-19 vaccines
Study: 36750904
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (800 mg acutely and 400 mg daily for a week)
Study: 36752055
Drug: Rapid molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rapid molecular drug susceptibility assays for linezolid, bedaquiline, clofazimine, nitroimidazoles (pretomanid and delamanid), and pyrazinamide
Study: 36752055
Drug: Sequencing assays
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequencing assays for novel and repurposed drug compounds
Study: 36752227
Drug: TMVr with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMVr with MitraClip implant plus guideline-directed medical therapy (GDMT)
Study: 36752714
Drug: Mindfulness-based music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based music therapy intervention
Study: 36753281
Drug: Gefitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib plus chemotherapy (pemetrexed with platinum)
Study: 36753698
Drug: Darolutamide 600
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darolutamide 600 mg twice a day
Study: 36753834
Drug: Apatinib 250
Normalized name: lapatinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 250 mg once daily and camrelizumab 200 mg once every two weeks intravenously every 28-day cycle
Study: 36754009
Drug: Tolvaptan and
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan and Octreotide-LAR (two 20-mg i.m. injections)
Study: 36754009
Drug: Tolvaptan and
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan and Placebo (two i.m. 0.9% saline solution injections)
Study: 36754158
Drug: Myo-inositol, probiotics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol, probiotics, and micronutrient supplement (vitamins B2, B6, B12, D, zinc)
Study: 36754158
Drug: Standard supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard supplement (folic acid, iron, calcium, iodine, β-carotene)
Study: 36754174
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg OPT-302 + 0.5 mg ranibizumab
Study: 36754174
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg OPT-302 + 0.5 mg ranibizumab
Study: 36754174
Drug: Sham +
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham + 0.5 mg ranibizumab
Study: 36755328
Drug: Continue standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue standard TNFi dosing
Study: 36755328
Drug: Fixed longer
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed longer dosing intervals of TNFi
Study: 36755418
Drug: Conventional (noncellular)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional (noncellular) therapies
Study: 36756676
Drug: Enavogliflozin 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enavogliflozin 0.3 mg/day
Study: 36756808
Drug: Quadrivalent seasonal
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent seasonal inactivated influenza vaccine
Study: 36756899
Drug: rFVIIa (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIa (recombinant activated factor VIIa; 80 μg/kg)
Study: 36757318
Drug: Azithromycin (2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (2-g oral dose)
Study: 36757390
Drug: Dasatinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (50 mg)
Study: 36757390
Drug: Dasatinib generic
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib generic (50 mg)
Study: 36757445
Drug: Sintilimab 200
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200 mg plus DEB-TACE
Study: 36757536
Drug: Firibastat 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firibastat 100 mg
Study: 36757536
Drug: Firibastat 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firibastat 500 mg
Study: 36757690
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid rectal spacer
Study: 36757706
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy (high-dose cytarabine)
Study: 36757755
Drug: Argatroban plus
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban plus alteplase (n=402); intravenous argatroban (100 μg/kg bolus over 3-5 minutes followed by an infusion of 1.0 μg/kg per minute for 48 hours) within 1 hour after alteplase (0.9 mg/kg; maximum dose, 90 mg; 10% as 1-minute bolus, remaining infused over 1 hour)
Study: 36758420
Drug: farletuzumab +
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: farletuzumab + chemotherapy
Study: 38671587
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + chemotherapy
Study: 36758570
Drug: Colesevelam (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam (625 mg overencapsulated tablets, starting dose of two capsules twice daily for 12 days, titrated to effect during the first 5 days)
Study: 36758612
Drug: Parenteral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral anticoagulants (92.1% of patients)
Study: 36758612
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (75.6% at discharge)
Study: 36758612
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists (6.7% at discharge)
Study: 36758713
Drug: Tablet-based application
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based application with feedback, monitoring, and progression
Study: 36759013
Drug: Neoadjuvant sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant sintilimab plus triplet chemotherapy (liposomal paclitaxel, cisplatin, and S-1) every 3 weeks for two cycles
Study: 36759013
Drug: Neoadjuvant sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant sintilimab plus triplet chemotherapy
Study: 36759673
Drug: T-VEC plus
Normalized name: T-Vec
DrugBank: Talimogene laherparepvec (DB13896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: T-VEC plus neoadjuvant chemotherapy (NAC)
Study: 36759720
Drug: Trabectedin/pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin/pegylated liposomal doxorubicin (TP) followed by platinum therapy at relapse
Study: 36759901
Drug: Intranasal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal infusion of neural stem cells (NSCs) with nasal patches and rehabilitation therapy
Study: 36759901
Drug: Rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation therapy only
Study: 36759902
Drug: INTERCARE intervention
Normalized name: Ivercare
Approvals — FDA: no, EMA: no, PMDA: no
Description: INTERCARE intervention with low fidelity to communication tools (e.g., ISBAR)
Study: 36760605
Drug: 0.6% compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6% compound lidocaine hydrochloride injection
Study: 36760794
Drug: S1 rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: S1 rTMS and SS alone or in combination
Study: 36760794
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of S1 rTMS and SS
Study: 36761900
Drug: Intranasal photodynamic
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal photodynamic therapy (PDT)
Study: 36762424
Drug: Peak hsTnI
Normalized name: PEAK FLOW METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak hsTnI <75 ng/L
Study: 36762424
Drug: Peak hsTnI
Normalized name: PEAK FLOW METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak hsTnI 75 ng/L to <1000 ng/L
Study: 36762424
Drug: Peak hsTnI
Normalized name: PEAK FLOW METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak hsTnI ≥1000 ng/L
Study: 36762424
Drug: Peak hsTnI
Normalized name: PEAK FLOW METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak hsTnI ≥75 ng/L
Study: 36762424
Drug: Peak hsTnI
Normalized name: PEAK FLOW METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak hsTnI ≥75 ng/L with ischemic features
Study: 36762424
Drug: Peak hsTnI
Normalized name: PEAK FLOW METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak hsTnI ≥75 ng/L without ischemic features
Study: 36762782
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus for 6 months
Study: 36762930
Drug: gp120-reactive monoclonal
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp120-reactive monoclonal antibodies (mAbs) isolated from participants
Study: 36762930
Drug: Vaccine-induced gp120-specific
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-induced gp120-specific antibody lineages
Study: 36763183
Drug: 12-week web-based
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week web-based dietary intervention with daily text messages
Study: 36763307
Drug: Extended interval
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended interval dosing (EID) of natalizumab (≤ 9 infusions/year)
Study: 36763307
Drug: Standard interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard interval dosing (SID) of natalizumab (≥ 11 infusions/year)
Study: 36763307
Drug: Extended interval
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended interval dosing (EID)
Study: 36763307
Drug: Standard interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard interval dosing (SID)
Study: 36763327
Drug: Acoziborole (20-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoziborole (20-1200 mg single oral dose)
Study: 36763327
Drug: Capsules versus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules versus tablets (in additional cohorts)
Study: 36763327
Drug: 960-mg tablet
Normalized name: hydrotalcite 960 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 960-mg tablet cohort (in additional cohorts)
Study: 36763359
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser therapy (CLT)
Study: 36763358
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg subcutaneous twice daily)
Study: 36763537
Drug: KPd (carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: KPd (carfilzomib 20/27 mg/m2, pomalidomide 4 mg, dexamethasone 40 mg)
Study: 36763879
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg (continuous dosing)
Study: 36763879
Drug: Baricitinib 2
Normalized name: baricitinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 2 mg (downtitration)
Study: 36763879
Drug: Placebo (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (treatment withdrawal, 4-mg cohort)
Study: 36763879
Drug: Baricitinib 2
Normalized name: baricitinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 2 mg (continuous dosing)
Study: 36763879
Drug: Baricitinib 1
Normalized name: baricitinib 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 1 mg (downtitration)
Study: 36763879
Drug: Placebo (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (treatment withdrawal, 2-mg cohort)
Study: 36763879
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg (downtitration)
Study: 36763879
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg (treatment withdrawal)
Study: 36763879
Drug: Baricitinib 2
Normalized name: baricitinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 2 mg (treatment withdrawal)
Study: 36763899
Drug: OnabotulinumtoxinA (ONA)
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA (ONA) injections (1.5 U/injection site)
Study: 36763919
Drug: Intravaginal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal treatment with gel containing 600 IU/mL of oxytocin
Study: 36763919
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (gel alone)
Study: 36764323
Drug: CYAD-01 (autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYAD-01 (autologous NKG2D-based CAR T-cell therapy)
Study: 36764326
Drug: Colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5 mg acute treatment (n=19)
Study: 36764326
Drug: Colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5 mg twice daily for 3 weeks (n=16)
Study: 36764326
Drug: Placebo acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo acute treatment (n=12)
Study: 36765309
Drug: Intervention components
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention components to support PWIDLH to reduce drug use and improve mental health and engagement in HIV care.
Study: 36765312
Drug: KopOpOuders-PTSD (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: KopOpOuders-PTSD (treatment as usual + intervention)
Study: 36765318
Drug: Oral arsenic
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral arsenic trioxide (oral-ATO)-based regimens
Study: 36765332
Drug: Suprachoroidal injection
Normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprachoroidal injection of 4 mg Triamcinolone Acetonide (TA)